# EDISON

# Spotlight - Update

# Ensurge Micropower

# Achieving commercialisation milestones

Ensurge Micropower's CEO took the opportunity in the recent Q322 results presentation to brief investors on the progress made delivering samples of complete packaged microbatteries to customers as well as sample unit cells to strategic partners. Management anticipates commercial production starting at the end of Q422 to fulfil customer demand in Q123.

## Losses widen as company prepares for production

Ensurge did not generate any revenues during the first nine months of FY22 (9M22). Payroll costs were \$1.4m higher year-on-year at \$6.8m as management increased spending on operations to support sampling and production readiness. This resulted in a widening of EBITDA losses, excluding share-based payments, by \$1.7m to \$12.5m. Investment in capital expenditure was only \$0.6m as most of the work adapting the roll-to-roll (R2R) facility for manufacturing microbatteries was completed in FY21. The free cash outflow totalled \$15.9m, leaving \$3.1m cash (gross excluding restricted cash) at end Q322.

## Cash runway extended into Q123

Following the private placement in November raising NOK55m gross (\$5.4m) at NOK2.0/share, management notes that Ensurge has sufficient funds to support operations into Q123. It is focused on signing an agreement with one of its strategic partners, which it anticipates will provide substantial funding for operations starting in Q123. Management notes that it is actively engaging multiple US investment banks to raise equity (value unspecified) into the California subsidiary to fund the expansion in production capacity required to meet anticipated demand from FY24 onwards.

## Valuation: Potential market of over 1bn units a year

Ensurge is initially targeting the medical wearables and hearables markets, followed by the connected sensor and sport & fitness wearables markets. Our scenario analysis calculates that a 5-10% share of these markets represents annual revenues of \$330-550m and EBITDA of \$211-365m. Management has stated that when the R2R factory in San Jose is fully utilised it could potentially generate EBITDA of more than \$100m, depending on product mix.

Historical financials						
Year end	Revenue (\$m)	EBITDA (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)
12/18**	3.4	(49.3)	(54.3)	(0.93)	0.00	N/A
12/19**	1.2	(30.6)	(35.9)	(0.61)	0.00	N/A
12/20	0.5**	(11.3)	(14.9)	(0.04)	0.00	N/A
12/21	0.0	(14.6)	(17.2)	(0.01)	0.00	N/A

Source: Company data. Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptionals and share-based payments. \*\*Discontinued business.

### Technology

ENSU

### 21 November 2022

Price	NOK2.20
Market cap	NOK517m

#### Share price graph



## Share details Code

Listing	OSLO & OTCQB
Shares in issue (following issue of 7 1 of shares from Private Placement	
Net debt (\$m) at 30 September 202 (excluding \$1.6m restricted cash, \$ finance leases and funds from priva placement)	11.2m

### **Business description**

Ensurge Micropower's solid-state lithium battery technology combines advanced energy cell design with proprietary materials and manufacturing innovation to produce thin, flexible batteries that can power safer and more capable wearable devices and connected sensors.

#### Bull

- Ensurge's solid-state batteries are highly suitable for the hearables and medical wearables markets.
- Markets for microbatteries are already established.
- When fully equipped, Ensurge's volume manufacturing facility should be able to generate c \$100m EBITDA.

### Bear

- Ensurge has yet to generate meaningful revenues from microbattery sales.
- Revenue growth dependent on companies incorporating microbatteries in their products.
- Funding from strategic partners not yet agreed.

#### Analyst

Anne Margaret Crow

+44 (0)20 3077 5700

tech@edisongroup.com Edison profile page

Ensurge Micropower is a research client of Edison Investment Research Limited



## Twin go-to-market strategy

## First packaged battery samples shipped

At the end of October, having solved the key challenges related to manufacturing packaged rechargeable microbatteries, Ensurge shipped its first packaged battery samples for evaluation. These samples were delivered to a leader in the hearing aid market. Since then, Ensurge has also shipped packaged battery samples to an innovative digital health device company, which is expected to require batteries for inclusion in its products during Q123, making it the first of Ensurge's customers to go into production. In contrast to the shipments of unit cells discussed below, the packaged microbatteries are formed from unit cells stacked on top of each other and sealed in a protective package with connectors. The prospective partners and customers evaluating Ensurge's technology are able to mount the complete microbatteries on printed circuit boards and evaluate how well they perform in prototype products.

During the first shipment phase, samples will be delivered to the five companies that have signed contracts with Ensurge and want the batteries for testing, evaluation and adoption. These include a Fortune 500 industrial company active in manufacturing capital equipment, a customer in the digital health market, two agreements in the medical hearables market and one in the broader wearables market. Management estimates that these collectively represent potential product revenue of over \$50m/year. These customers are interested in complete microbatteries in the 1–100 mAh range, which can provide faster charging or higher energy density than conventional rechargeable microbatteries, can be mounted on customers' circuit boards using conventional reflow assembly techniques (unlike typical lithium-ion coin cell batteries) or can be customised to create novel form factors such as rings. These form factors are only achievable with batteries formed on a flexible substrate such as the ultra-thin steel substrate used by Ensurge. In a subsequent phase, the samples will be offered to customers that have shown strong interest in the Ensurge microbattery's performance but have not yet signed agreements. Ensurge is currently in discussions with more than 20 new potential microbattery customers, collectively representing over \$200m in potential annual product revenue. This is more than the capacity of the San Jose fabrication facility when fully equipped.

We note that management expects that the initial revenues will be attributable to smaller companies with faster development cycles where the flexibility of form factor offered by Ensurge's microbattery technology is essential. The larger companies with longer development cycles are likely to introduce products incorporating Ensurge's microbatteries in H223.

## Unit cells shipped to strategic partners

In August Ensurge announced that it was complementing potential sales of complete packaged microbatteries with potential sales of its core microbattery building block, referred to as the 'unit cell'. It is in active discussions with four large multinational corporations that are interested in unit cells rather than packaged batteries because each of them has technology that could be combined with Ensurge's core cell technology to create solutions enabling applications yet to exist. These applications expand the market beyond the one-billion-unit market discussed below. Ensurge has already shipped unit cells in a conventional coin cell format to ease testing and evaluation to three of these strategic partners, one of which is a multinational consumer electronics and communications company and two are battery manufacturers targeting the wearables, hearables and internet-of-things (IOT) markets. The fourth strategic partner, which Ensurge is currently in contract negotiations with, is a global information and communications technology corporation.

Ensurge is focused on signing funded development agreements with the two consumer device companies and licensing agreements with the two battery companies, though funded development



agreements are also an option for these partners. Management expects the partnership discussions to accelerate now three of the partners have commenced their evaluation of the unit cells. As shown in the company's November 2022 presentation, the two consumer device companies collectively represent over \$500m in potential annual revenues for Ensurge. The two battery companies collectively represent over \$500m in potential revenues if a technology licensing model is adopted. We note that there is a pipeline of several other potential strategic investors.

## Funded development beyond current roadmap

Ensurge is currently engaged in contract negotiations with a global leader in the information technology market to undertake funded technology development, which will potentially deliver technology attributes at the unit cell level beyond Ensurge's current roadmap. This development work will be defined to meet the demands of the third party's aggressive wearable device roadmap, potentially delivering substantial improvements with regards to usability.

## Financing

## Cash runway extended into Q123

In July, the company announced funding of NOK57m gross (\$5.7m), of which NOK46.7m was from convertible loans bearing 5% interest with a conversion price of NOK3.00/share and NOK10.3m from a private placement at NOK3.00/share. Management estimated that this activity would provide sufficient funds to support operations into Q422. In November Ensurge completed a private placement raising c NOK55m (\$5.4m) (gross) at NOK2.0/share. The placement is split into two tranches, the second of which is subject to approval at an extraordinary general meeting (EGM) on 1 December 2022. The net proceeds will be used to fund the company's operations and development work. Ensurge also intends, subject to approval at the EGM, to raise up to NOK15m (\$1.5m), also at NOK2.0/share, through a subsequent offering to eligible shareholders.

# Operating costs to be supported by strategic partners from Q123

Management aims to secure at least one long-term, funded technology development agreement with a strategic partner, which, together with revenues from customers, will significantly contribute towards coverage of the company's cash expenses. It is focused on signing an agreement with one of its strategic partners, which management is targeting to provide substantial funding starting in Q123. If a strategic partnership is not in place soon enough, or if it does not provide sufficient funding, the company intends to raise additional funds from financial investors to cover operating costs.

## Potential fund-raising for capacity expansion

Management noted a strong increase in the production rate of battery cells during Q322, which it expects to increase further during Q422 and FY23. This capacity should be sufficient to meet customer demand during FY23. However, management expects that additional capacity will be required from FY24 onwards, which will require Ensurge to start placing orders for critical pieces of equipment in early FY23. Consequently, management notes that it is actively engaging multiple US investment banks to raise equity into the California subsidiary to fund this capital investment. Management has not stated how much equity would need to be raised to cover capacity expansion. In addition, Ensurge may also outsource some of the final steps in manufacturing complete batteries to gain extra capacity.



## **Management changes**

In August Ensurge announced the appointment of Tarun Anand as acting CFO, replacing Dave Williamson, who has retired after almost three years as acting CFO. Tarun has more than 20 years' experience in finance leadership at both established corporations, such as Hewlett Packard and Thermo Fisher, as well as several pre-IPO start-up firms.

# Valuation: Addressing a market of over 1bn units/year

We continue to present a scenario analysis rather than a formal valuation based on peer multiples because Ensurge does not expect to generate revenues from its solid-state battery technology until Q123. Referencing research from IDTechEx and others, management notes that the medical wearables, hearables, connected sensor and sport & fitness wearables markets are predicted to grow to more than one billion units per year by 2025. This excludes applications addressed by strategic partners (see above) rather than microbattery customers.

As discussed in our <u>March note</u>, these markets require batteries in the 1mAh to 70mAh capacity range. This capacity range is already covered by conventional lithium-ion batteries, although the relative size of lithium-ion batteries compared to solid-state batteries makes it likely that a material percentage of device manufactures will elect to pay a premium for the solid-state option. Ensurge has had detailed conversations with potential customers with which it has shared design details and in H121 stated that it believed a price of \$3–10/unit was achievable.

Exhibit 1: Potential annual revenues from milliwatt hour market (\$m)							
		Market share (%)					
		1%	3%	5%	7%	10%	
	1	11	33	55	77	110	
	2	22	66	110	154	220	
Price/unit	3	33	99	165	231	330	
(\$)	5	55	165	275	385	550	
	7	77	231	385	539	770	
	10	110	330	550	770	1,100	

Source: Edison Investment Research

Our scenario analysis presents the annual revenues realisable from these markets for a range of unit prices and levels of market penetration. Our analysis shows that a 5–10% share of these markets at a \$3–10 price range represents annual revenues of \$330–550m. Based on previous management guidance of c \$20m fixed costs (current levels are \$16.7m) and 30% variable costs, this gives an EBITDA range of \$211–365m. Management notes that when the R2R factory in San Jose is fully equipped and utilised it should be able to output several hundred million mAh of batteries each year, potentially generating EBITDA of more than \$100m depending on product mix.



Exhibit 2: Financial summary				
	m 2018*	2019*	2020	2021
Year-end 31 December	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS				
Revenue	3.4	1.2	0.5*	0.0
EBITDA	(49.3)	(30.6)	(11.3)	(14.6)
Operating Profit (before amort. and except.)	(53.3)	(34.5)	(11.4)	(14.6)
Intangible Amortisation	0.0	0.0	0.0	0.0
Exceptionals	(15.6)	(42.4)	0.0	0.0
Share-based payments	(1.8)	(0.2)	(0.7)	(4.9)
Operating Profit	(70.6)	(77.1)	(12.0)	(19.6)
Net interest	(1.1)	(1.4)	(3.6)	(2.6)
Exceptional charges relating to issue of warrants	0.0	0.0	(23.2)	(8.8)
Profit Before Tax (norm)	(54.3)	(35.9)	(14.9)	(17.2)
Profit Before Tax (FRS 3)	(71.7)	(78.5)	(38.8)	(31.0)
Tax	(0.0)	0.0	0.0	0.0
Profit After Tax (norm)	(54.4)	(35.9)	(14.9)	(17.2)
Profit After Tax (FRS 3)	(71.7)	(78.4)	(38.8)	(31.0)
Average Number of Shares Outstanding (m)	58.6	58.6	393.2	1,368.3
EPS - normalised (\$)	(0.93)	(0.61)	(0.04)	(0.01)
EPS - (IFRS) (\$)	(1.22)	(1.34)	(0.10)	(0.02)
Dividend per share (\$)	0.00	0.00	0.00	0.00
EBITDA Margin (%)	N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)	N/A	N/A	N/A	N/A
BALANCE SHEET				
Fixed Assets	35.3	0.6	0.8	2.6
Intangible Assets	2.4	0.0	0.0	0.0
Tangible Assets	22.5	0.0	0.2	2.0
Other	10.4	0.6	0.6	0.6
Current Assets	44.1	11.7	6.9	8.7
Stocks	2.6	0.0	0.0	0.0
Debtors	8.9	2.8	1.1	1.8
Cash excluding restricted cash	31.0	7.3	4.2	5.3
Restricted cash	1.6	1.6	1.6	1.6
Current Liabilities	(8.1)	(6.8)	(32.7)	(8.0)
Creditors	(8.1)	(5.5)	(29.5)	(4.1)
Short term borrowings	0.0	(1.4)	(3.2)	(3.9)
Long Term Liabilities	(11.5)	(25.1)	(21.9)	(16.8)
Long term borrowings excluding finance leases	0.0	(11.8)	(9.7)	(5.9)
Other long-term liabilities	(11.5)	(13.2)	(12.2)	(10.9)
Net Assets	59.7	(19.7)	(46.9)	(13.4)
CASH FLOW		, ,	. ,	
Operating Cash Flow	(52.3)	(29.1)	(11.9)	(14.6)
Net Interest	0.3	(1.4)	(11.3)	(14.0)
Tax	(0.1)	0.0	0.0	0.0
Capex	(0.1)	(5.1)	(0.3)	(1.8)
Acquisitions/disposals	0.0	0.0	0.0	0.0
Financing	(0.0)	0.0	13.3	25.2
Dividend payments and Other items	(0.0)	0.0	0.0	0.0
Net Cash Flow	(64.9)	(35.5)	(2.1)	5.6
Opening net debt/(cash) excluding finance leases and restricted cash	(96.5)	(35.5)	(2.1)	8.8
Finance leases initiated	(96.5)	(31.0)	0.0	0.0
Other				
	(0.6)	(1.4)	(0.7)	(1.3)
Closing net debt/(cash) excluding finance leases and restricted cash	(31.0)	5.9	8.8	4.5



#### General disclaimer and copyright

This report has been commissioned by Ensurge Micropower and prepared and issued by Edison, in consideration of a fee payable by Ensurge Micropower. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

#### Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

#### **New Zealand**

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

#### **United Kingdom**

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment or investment relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

#### **United States**

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provide is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, purfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom

New York +1 646 653 7026 1185 Avenue of the Americas 3rd Floor, New York, NY 10036 United States of America Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia